anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Callout

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 96,741
Current window 74,401-74,430
Pages 3,225
Rows per page 30
Component: Calloutclear collectionreset all
18 30 60

Component

74,401-74,430 of 96,741

filter-aware
55
The slide uses a calculation of daily doses sold based on revenue and price to derive a rate, then compares this against historical data from a Lancet study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
58
Includes a visual comparison of pharmacophore models and a specific reference to ABT-239.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
59
The slide highlights a fundamental design constraint in medicinal chemistry.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
60
The slide uses visual evidence to link a specific chemical moiety (piperidine) to a known safety liability (hERG blockade).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
61
The slide uses a combination of narrative text and a supporting data table to argue that certain structural features are predictive of drug safety risks.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
62
The slide highlights the specific chemical challenge of nitrogen basicity in piperidine rings and the potential for fluorine to modulate pKa for improved safety.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
63
The slide uses a screenshot of a blog post with red underlines to emphasize key quotes about hERG activity and piperidine.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
64
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
66
The slide uses a 'quote-and-commentary' structure to expose potential corporate malfeasance or negligence.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
67
The slide uses historical publication data to cast doubt on the quality of the drug pitolisant by highlighting that the inventor prioritized other compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
69
The slide uses a question as a hook to frame the subsequent investigation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
71
The slide uses a combination of chemical structure diagrams, a tabular summary of clinical trial failures, and a pie chart showing the distribution of indications for failed trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
72
The slide highlights BF2.649 (pitolisant) with a red box to emphasize its drug-likeness profile compared to other failed candidates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
73
The slide uses a 'preempt_rebuttal' strategy by highlighting that even industry giants failed where the current subject company is operating.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
76
The slide uses excerpts from scientific literature to frame the technical hurdles in CNS drug development.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
77
The slide uses a 'villain critique' approach by leveraging a peer's own research to undermine the target's (Bioprojet/pitolisant) technology.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
78
The slide is currently empty of content other than the title, suggesting it is a placeholder or a transition slide for a section on competitor failures.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
81
The slide uses a direct quote from a scientific paper to undermine the viability of the drug candidate mentioned in the lower text block.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
82
The slide uses a 'villain critique' style to undermine the target drug (pitolisant) by associating it with failed industry-wide efforts.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
83
The slide uses a Q&A format to present expert testimony as evidence of product failure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
84
The slide uses a Q&A transcript format to build a case against the efficacy of pitolisant based on historical failures at Abbott.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
85
The slide uses a Q&A format to build a case against the drug's efficacy based on metabolic pathways.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
86
The slide uses a Q&A format to frame the failure as a known, expected outcome rather than a surprise, highlighting the difficulty of the H3 class.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
87
The slide uses a Q&A transcript format to validate the thesis that the drug class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
88
Uses expert quotes to establish a 'villain' (the drug class/mechanism) and preemptively rebut its efficacy.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
89
The slide uses expert testimony to undermine the credibility of the company (Bioprojet) and the drug (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
90
The slide uses a Q&A transcript format to validate a negative thesis about the viability of H3 receptor programs.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
91
The slide uses a Q&A transcript format to validate the thesis that the H3 receptor class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
92
The slide uses a Q&A transcript format to highlight a specific failure case study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
93
The slide uses a Q&A format to build a case against the safety of a drug program.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit